Core Insights - Eosinophilic Esophagitis (EoE) is a rapidly increasing digestive disorder affecting over 450,000 people in the United States, leading to significant healthcare burdens and mental health issues [3][4]. Company Overview - Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing locally delivered, extended-release products to address high unmet medical needs [4]. - The company utilizes its proprietary DiffuSphere™ technology for optimized drug delivery, aiming to improve safety, tolerability, efficacy, and duration of effect for existing and novel drugs [4]. Product Development - Eupraxia's EP-104GI is currently in a Phase 1b/2a trial (RESOLVE trial) for treating EoE, utilizing a unique injection method for local drug delivery [5]. - The company has also completed a Phase 2b clinical trial (SPRINGBOARD) for EP-104IAR, targeting pain from knee osteoarthritis, achieving its primary endpoint and three of four secondary endpoints [5]. - Eupraxia is developing a pipeline of long-acting formulations for various indications, including inflammatory joint diseases and oncology [5]. Upcoming Events - Eupraxia's CEO, Dr. James A. Helliwell, will present at a Tribe Public Webinar on November 15, 2024, discussing EoE and its implications [1][2].
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024